Superworth

Alnylam Pharmaceuticals price to book ratio ALNY

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
22.1×
10-year median
10.9×
Against its 10-year history
70th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.8× to 191×
Peer median
5.1×

Alnylam Pharmaceuticals' price to book ratio is 22.1× as of Oct 23, 2026.

That is above its ten-year median of 10.9×, higher than on 70% of days in the last ten years.

Over that time it ranged from 2.8× in Oct 2016 to 191× in Jan 2026.

The median for 10 biotech stocks of a similar size is 5.1×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far22.1×20.3×191×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022136×20.9×159×
202126.8×14.0×30.8×
202012.4×7.9×13.8×
20198.2×4.6×8.6×
20184.8×4.3×11.8×
201711.1×3.2×12.3×
20163.2×2.7×6.1×
20156.0×4.8×10.6×
20148.3×4.2×21.4×
201313.9×5.1×14.2×
20125.2×2.6×5.8×
20112.7×2.0×3.0×
20102.6×2.4×3.8×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
ALNYAlnylam Pharmaceuticals22.1×
UTHRUnited Therapeutics3.9×
INCYIncyte3.7×
ONCBeOne Medicines8.3×
EXELExelixis8.7×
NBIXNeurocrine Biosciences3.9×
HALOHalozyme Therapeutics99.3×
TECHBIO-TECHNE5.4×
REGNRegeneron Pharmaceuticals2.6×
RGENRepligen4.7×
KRYSKrystal Biotech6.8×
Peer median5.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.